ÂÜÀòÂÒÂ×

Kevin Herlihy has worked in various roles in the pharmaceutical industry since 2010. In 2010, they were a Senior Research Associate at UNC Chapel Hill, where they authored preclinical animal research protocols and a pulmonary delivery grant, as well as managed academic projects. In 2012, they joined Liquidia Technologies as a Scientist, where they designed, formulated, manufactured, and scaled up a dry powder inhalation product, improving yield, robustness, and aerosol properties while eliminating organic solvents and extraneous purification steps. In 2013, they became a Senior Scientist at Envisia Therapeutics (a Liquidia spin out company), where they developed an ophthalmic sustained release, monoclonal antibody product and improved protein stability through reformulation. Kevin also scaled up the mAb process. In 2014, they were promoted to Director, Formulation Technology at Lq3 Pharmaceuticals (another Liquidia spin out company), where they formulated an oral health radioprotection product and compared technologies for localized drug delivery, managing consultants, CROs, and CMOs to expedite product development. In 2016, they returned to Liquidia Technologies as a Principal Scientist, where they developed recombinant protein and small molecule drug products and facilitated Phase 3/Pre-NDA process development, including risk analysis, root cause analysis, PAT and CPP control systems development, process scale up, cGMP manufacturing, and authored and reviewed reports, SOPs, batch records, and NDA leaf documents. In 2020, they joined Liquidia Corporation as Director, PRINT Process Engineering, and in 2021 they were promoted to Senior Director of Process Development at Glycomine Inc.

Kevin Herlihy earned their Ph.D. in Chemistry from the University of North Carolina at Chapel Hill and their Bachelor of Science degree in Chemistry and Environmental Studies from UC Santa Barbara.